# Anti-Platelets

1. **Cyclooxygenase (COX) inhibitors**
   - Irreversibly inhibit platelet COX-1 → ↓ thromboxane A₂ (TXA₂) synthesis → ↓ platelet aggregation
   - `Aspirin`

1. **ADP receptor (P2Y₁₂) antagonists**
   - Block ADP binding to P2Y₁₂ receptor → inhibit activation of GPIIb/IIIa receptors
   - `Clopidogrel`, `Prasugrel`, `Ticagrelor`, `Ticlopidine`

1. **GPIIb/IIIa receptor antagonists**
   - Directly block fibrinogen binding to GPIIb/IIIa receptor on platelet surface → inhibit final common pathway of aggregation
   - `Abciximab`, `Eptifibatide`, `Tirofiban`

1. **Phosphodiesterase inhibitors**
   - ↑ cAMP in platelets → ↓ platelet aggregation and cause vasodilation
   - `Dipyridamole`, `Cilostazol`

1. **Thromboxane synthase inhibitors / receptor blockers**
   - ↓ TXA₂ formation or block TXA₂ receptors
   - `Picotamide`, `Ridogrel`

1. **PAR-1 (Protease-activated receptor-1) antagonists**
   - Inhibit thrombin-mediated platelet activation
   - `Vorapaxar`

![Anti-platelets](/pharmacology/cvs/anti-platelets/anti-platelets.png)
